CGMP/Finished Pharmaceuticals/Adulterated
Similar Posts
FDA/MHRA/Health Canada Symposium: Regulatory perspectives in good clinical practice, bioequivalence and good pharmacovigilance practice – 06/02/2026
This symposium will highlight current and emerging topics of interest to the industry related to good clinical practice, bioequivalence and good pharmacovigilance practice.FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reaGuidance Documents for Drug Applications
Guidance documents are prepared for FDA review staff and applicants/sponsors to provide guidelines to the processing, content, and evaluation/approval of applications and also to the design, production, manufacturing, and testing of regulated products.Rhino Gummy Royal 50000 may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Rhino Gummy Royal 50000, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.First Generic Drug Approvals
Each year, FDA’s Center for Drug Evaluation and Research (CDER) approves a wide range of new drug products. FDA provides the scientific and regulatory advice needed to bring safe, effective, high-quality generic alternatives to market, which in turn creates more affordable treatment options for patiCDER Manual of Policies & Procedures | MAPP
CDER’s Manual of Policies and Procedures (MAPPs) are federal directives and documentation of internal policies and procedures.